Rathbones' head of collectives research Mona Shah asks if precision medicine is a reality or just wishful thinking.
In the late 1990s, advances in research and development (R&D) promised to revolutionise the pharmaceutical industry. Scientists were on the cusp of mapping the human genome, which is the DNA 'genetic barcode' containing the information to build, repair and run our bodies. It also contains clues about things that might go wrong as we age and which medicines might work best for us. It was believed this would enable us to take a big step towards personalised medicine (also known as precision medicine) and away from the existing 'one-size-fits-all' model of the past. Woodford buys ...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
